NCT02556437View on ClinicalTrials.gov

Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Multifocal Motor Neuropathy

Interventions

DRUG

HyQvia

Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection

DRUG

Subcuvia

Human immunoglobulin 16% for subcutaneous injection

Trial Locations (2)

2100

Department of Neurology, Rigshospitalet, Copenhagen

8000

Department of Neurology, Aarhus University Hospital, Aarhus C

All Listed Sponsors

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Johannes Jakobsen

OTHER

NCT02556437 - Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) | Biotech Hunter | Biotech Hunter